Overview

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Status:
Withdrawn
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Ipilimumab
Linrodostat
Nivolumab